key: cord-0994727-l0nrz9t0
authors: Tsitsiklis, Alexandra; Zha, Beth; Byrne, Ashley; DeVoe, Catherine; Levan, Sophia; Rackaityte, Elze; Sunshine, Sara; Mick, Eran; Ghale, Rajani; Jauregui, Alejandra; Neff, Norma; Sarma, Aartik; Serpa, Paula; Deiss, Thomas; Kistler, Amy; Carrillo, Sidney; Ansel, K. Mark; Leligdowicz, Aleksandra; Christenson, Stephanie; Jones, Norman; Wu, Bing; Darmanis, Spyros; Matthay, Michael; Lynch, Susan; DeRisi, Joseph; Consortium, COMET; Hendrickson, Carolyn; Kangelaris, Kirsten; Krummel, Matthew; Woodruff, Prescott; Erle, David; Rosenberg, Oren; Calfee, Carolyn; Langelier, Charles
title: Impaired immune signaling and changes in the lung microbiome precede secondary bacterial pneumonia in COVID-19
date: 2021-04-23
journal: Res Sq
DOI: 10.21203/rs.3.rs-380803/v1
sha: 2887cbd6fc4925f1b213296ea54dcefafdf25c99
doc_id: 994727
cord_uid: l0nrz9t0

Secondary bacterial infections, including ventilator-associated pneumonia (VAP), lead to worse clinical outcomes and increased mortality following viral respiratory infections including in patients with coronavirus disease 2019 (COVID-19). Using a combination of tracheal aspirate bulk and single-cell RNA sequencing (scRNA-seq) we assessed lower respiratory tract immune responses and microbiome dynamics in 28 COVID-19 patients, 15 of whom developed VAP, and eight critically ill uninfected controls. Two days before VAP onset we observed a transcriptional signature of bacterial infection. Two weeks prior to VAP onset, following intubation, we observed a striking impairment in immune signaling in COVID-19 patients who developed VAP. Longitudinal metatranscriptomic analysis revealed disruption of lung microbiome community composition in patients with VAP, providing a connection between dysregulated immune signaling and outgrowth of opportunistic pathogens. These findings suggest that COVID-19 patients who develop VAP have impaired antibacterial immune defense detectable weeks before secondary infection onset.

Secondary bacterial pneumonia results in significant morbidity and mortality in patients 57 with viral lower respiratory tract infections (LRTI) 1 . This problem was evident in the 1918 influenza 58 pandemic during which the majority of deaths were ultimately attributed to secondary bacterial 59 pneumonia 2 . SARS-CoV-2 infection, like influenza, confers an increased risk of late onset 60 secondary bacterial infection, often manifesting as ventilator-associated pneumonia (VAP) 3 . 61

Marked heterogeneity exists with respect to the risk of VAP in patients with coronavirus disease 62 2019 (COVID-19), with incidence ranging from 12-87% between published cohort studies 4-7 . 63

The mechanisms underlying VAP susceptibility in COVID-19 remain unknown, and no 64 biomarkers yet exist to inform risk of VAP at the time of intubation. Animal models of influenza 65 may provide some insight, suggesting a role for interferon-mediated suppression of cytokines 66 essential for bacterial defense, including neutrophil recruitment, antimicrobial peptide production 67 and the Th17 response [8] [9] [10] . Few human immunoprofiling studies have been conducted in VAP 68 however, and none have been reported in a prospective cohort of COVID-19 patients. 69

Lower respiratory infections represent a dynamic relationship between pathogen, host 70 response and the lung microbiome 11 . Despite their interconnected roles, no studies to date have 71 simultaneously profiled host immune responses and lung microbiome dynamics in the context of 72 VAP. For instance, while prior work has described lung microbiome disruption in patients with 73 VAP 11, 12 , the question of whether host immune responses following viral infection may contribute 74 to this dysbiosis, leading to subsequent infection, remains unanswered. 75

Given the marked heterogeneity in VAP incidence among patients with COVID-19 4-7 , as 76 well as gaps in mechanistic understanding of secondary bacterial pneumonia, we sought to 77 assess the molecular determinants of VAP in the setting of SARS-CoV-2 infection. We employed 78 a systems biology approach involving immunoprofiling the host transcriptional response and 79 simultaneously assessing lung microbiome dynamics, using a combination of bulk and single cell 80 RNA sequencing and extensive clinical phenotyping. We observed a striking impairment in 81 antibacterial immune signaling at the time of intubation, that correlated with disruption of the lung 82 microbiome, weeks before the onset of VAP. 83

We conducted a prospective case-control study of adults requiring mechanical ventilation 86 for COVID-19 or for illnesses other than pneumonia. Of 84 patients with COVID-19 initially 87 enrolled, tracheal aspirate (TA) specimens from 28 patients met inclusion criteria for analysis 88 (Methods, Figure 1 ). In addition, eight critically ill patients from a second cohort (Study 2, 89 Methods) were included as controls. Patients were enrolled at one tertiary care hospital and one 90 safety net hospital in San Francisco, California under research protocols approved by the 91 University of California San Francisco Institutional Review Board (Methods). We collected TA 92 periodically following intubation and performed bulk and scRNA-seq (Methods). 93

Patients with VAP were adjudicated using the United States Centers for Disease Control 94 (CDC) definition 13 , including a requirement for a positive bacterial TA culture (N=10). Patients who 95 met CDC VAP criteria but had negative bacterial TA cultures were only included in a secondary 96 analysis (N=5). We defined onset of VAP as the first day a patient developed any of the criteria 97 used to meet the definition, in accordance with CDC guidance. Patients who did not meet the 98 CDC-NHSN criteria for VAP, and for whom there was no sustained clinical suspicion for bacterial 99 pneumonia during the admission, were adjudicated as No-VAP (N=13). 100

We compared lower respiratory tract host transcriptional responses between the VAP and 101

No-VAP groups at two time points. "Early" time point TA samples were collected a median of two 102 days post-intubation and 17 days before VAP onset (bulk RNA-seq analysis) or nine days before 103 VAP onset (scRNA-seq). "Late" time point samples were collected a median of two days before 104 VAP onset for both bulk and scRNA-seq analyses and compared against samples collected from 105

No-VAP patients at similar timepoints post-intubation (Figure 1, Table S1 , Table S2 ). We 106 additionally evaluated eight intubated patients with non-pneumonia illnesses as controls at the 107 "early" time-point. There were no significant differences between groups with respect to age, 108 gender, race or ethnicity (Table S1, S2 ). In addition, there were no differences between groups 109 with respect to in-hospital receipt of any immunosuppressant or antibiotics prior to sample 110 collection (Table S3) . 111 112 COVID-19 VAP is associated with a transcriptional signature of bacterial infection two days 113 before VAP onset 114

We began by assessing the lower respiratory host transcriptional response two days 115 preceding VAP onset in COVID-19 patients. Differential gene expression analysis was carried out 116 on TA bulk RNA-seq data from five patients who developed VAP (samples collected a median of 117 two days before VAP onset) and eight patients who did not develop VAP collected within a similar 118 time frame after intubation (Table S1) hours preceding VAP onset, we next asked whether differences in host immune signaling might 131 exist even earlier, two or more weeks before clinical diagnosis of VAP, and whether such 132 differences might explain the increased susceptibility to secondary bacterial infection in these 133 patients. We thus compared TA gene expression soon after the time of intubation between 134 patients who eventually developed VAP (samples collected a median of two days post-intubation, 135 17 days before VAP onset, n= 4) and patients who did not develop VAP (samples collected a 136 median of two days after intubation, n = 8) (Table 1) . We identified 154 differentially expressed 137 genes at FDR <0.1. The COVID-19 patients who developed VAP had lower expression of several 138 genes with roles in innate immunity including IFI30, MMP2, TLR9, and DEFB124 ( Figure 3A) . 139 GSEA further revealed that patients who developed VAP had lower expression of pathways 140 related to antibacterial immune responses including neutrophil degranulation, toll-like receptor 141 signaling, IL-17 signaling, antigen presentation and complement pathways and higher expression 142 of IFN-alpha/beta signaling pathways, more than two weeks before the onset of VAP ( Figure 3B ). 143

Additionally, pathways related to adaptive immunity such as T and B cell receptor signaling were 144 also downregulated in patients who subsequently developed VAP ( Figure 3B) . 145

To gauge the degree of immune signaling suppression compared to controls, we 146 performed a similar analysis on critically ill intubated patients without infection ( Figure 3C) . 147

Relative to the control group, multiple antibacterial immune pathways were downregulated in 148 COVID-19 patients, with the greatest attenuation in the VAP group ( Figure 3C ). Upstream 149 regulator analysis identified impaired activation of diverse cytokines in those with VAP, while 150 IFNB1 was notably upregulated ( Figure 3D ). Several pro-inflammatory cytokines were 151 downregulated in both groups compared to the controls ( Figure S1 ). We expanded the 152 comparison at the "early" time-point to include patients with culture-negative VAP (VAP: n=6, No-153 VAP: n=11) and observed similar differences at the pathway level ( Figure S2) . 154

Given prior reports demonstrating correlation between SARS-CoV-2 viral load and 155 interferon related gene expression 14 we next asked whether viral load differed between VAP and 156

No-VAP patients. No differences in SARS-CoV-2 qPCR or viral reads per million (rpM) in bulk 157 RNA-seq data were found in the days following intubation (P = 0.84 (RNA-seq), P = 0.53 (PCR), 158 Figure S3 ). We also considered the possibility that differences in the number of days of steroid 159 exposure prior to sample collection might explain results, but found no differences (P = 0.343) 160 (Table S1) . 161 COVID-19 VAP is associated with impaired anti-bacterial immune signaling in monocytes, 163 macrophages and neutrophils 164

To further understand the mechanism of early downregulation of key pathways involved 165 in antibacterial responses, we next asked whether this was driven by any one local immune cell 166 type. We performed scRNA-seq on TA specimens obtained early during disease course (median 167 of nine days before VAP) and enriched for immune cells using CD45 selection (Methods). We next investigated temporal dynamics of the lower airway host inflammatory response 209 in COVID-19 patients from the time of intubation to development of VAP by evaluating differential 210 gene expression between COVID-19 VAP patients at the "early" time point (median of 17 days 211 before VAP onset, n=4) versus "late" time point (median of two days before VAP onset, n=5) by 212 bulk RNA-seq. We identified 2705 differentially expressed genes (FDR<0.1) and unsupervised 213 hierarchical clustering of the 50 most significant genes demonstrated clear separation of the two 214 time-points ( Figure 5A ). GSEA revealed that type I interferon signaling was notably 215 downregulated at the "late" time-point most immediately preceding VAP onset in comparison to 216 the "early" timepoint ( Figure 5B) ; however, expression was still significantly higher than in the 217

No-VAP patients ( Figure 2B ). Several other immune signaling pathways were more highly 218 expressed at this "late" time-point, presumably reflecting activation of an antibacterial response 219 in the setting of bacterial pneumonia ( Figure 5B ). Consistent with this, upstream regulator 220 analysis indicated increased activation of several pro-inflammatory cytokines and decreased 221

IFNa and IFN-l signaling at the "late" versus "early" time-points ( Figure 5C ). 222

In contrast, comparing No-VAP patients at the "early" (n=8) versus "late" (n=8) time-points 223 yielded only two genes with a padj <0.1, both of which were interferon-stimulated genes (RSAD2 224 and CMPK2) downregulated at the "late" time-point, suggesting that while the host response was 225 relatively unchanged in these patients, the antiviral response attenuated over time. Indeed, GSEA 226 revealed that type I interferon signaling, and other antiviral immune pathways were downregulated 227 in the patients who did not develop VAP at the later time-point ( Figure S7 ). 228

Next, we performed a similar comparison between the "early" and "late" time-points based 229 on scRNA-seq data from patients who developed VAP. Differential gene expression analysis on 

We hypothesized that the innate immune suppression in patients who developed VAP 254 would correlate with viral load. Using TA metatranscriptomics to assess the lower respiratory 255 microbiome, we evaluated longitudinal changes in SARS-CoV-2 abundance. Although no 256 difference was observed at the "early" timepoint ( Figure S3 ), the trajectory of SARS-CoV-2 viral 257 load differed significantly in patients who developed VAP (p=0.0058), although in both groups 258 decreased over time ( Figure 6A ). This result suggested that COVID-19 patients who develop 259 VAP may exhibit impaired ability to clear virus compared to those who do not, and that the lung 260 microbiome composition may be similarly impacted. 261 Indeed, COVID-19 patients who developed VAP exhibited a significant reduction in 262 bacterial diversity of their airway microbiome up to three weeks before clinical signs of infection 263 (Shannon Diversity Index, p=0.012; Figure 6B ). COVID-19 patients who developed VAP also had 264 lower airway microbiome compositions more closely resembling each other than those from 265 patients who did not develop VAP, across all timepoints since intubation (Bray Curtis index, 266 p=0.0033; Figure 6C ), suggesting community collapse precedes the development of VAP. All 267 patients received antibiotics prior to collection of the first sample, suggesting that antibiotic use 268 was not driving these differences (Table S1) . Two days before VAP onset, a transcriptional signature consistent with bacterial infection 280 was observed. This finding suggests that host response changes can occur before clinical 281 recognition of pneumonia, highlighting the potential utility of the host transcriptome as a tool for 282 VAP surveillance. While intriguing, this observation did not provide an explanation for differential 283 susceptibility of some COVID-19 patients to post-viral pneumonia. 284

The discovery of an early suppressed antibacterial immune response in patients who later 285 developed VAP did however, offer a potential explanation. More than two weeks before VAP 286 onset, we observed a striking suppression of pathways related to both innate and adaptive 287 immunity, including neutrophil degranulation, TLR signaling, complement activation, antigen 288 presentation, and T cell receptor and B receptor signaling, as well as cytokine signaling (e.g. IL-289 1, IL-4, IL-12, IL-13 and IL-17). Comparison against uninfected, intubated controls confirmed the 290 previously described paradoxical impairment in immune signaling found in patients with severe 291 COVID-19 18 , and suggested that VAP susceptibility may be the result of disproportionate 292 suppression of innate and adaptive pathways critical for antibacterial defense, resulting in 293 enhanced susceptibility to opportunistic secondary infections. 294

Animal models of influenza have provided insight into potential mechanisms of post-viral 295 pneumonia, although none have provided insight regarding why some individuals are more 296 susceptible than others. In mice inoculated with influenza, for instance, virus-induced type I IFN 297

suppresses neutrophil chemokines and impairs Th17 immunity, compromising effective clearance 298 of bacterial infections 9,10 . Interestingly, we also observed increased type I interferon signaling in 299 COVID-19 patients who weeks later developed VAP, and a strikingly similar impairment in Th17 300 signaling and other immune pathways. Desensitization to toll-like receptor (TLR) ligands after 301 influenza infection has also been documented 20 , which is congruent with the downregulation of 302 TLR signaling at the time of intubation observed in our bulk RNA-seq analyses. 303 Impaired bacterial clearance by alveolar macrophages was found to be driven by virus-304 related IFNg production by T cells 21 in a murine post-influenza model. In contrast, we found that 305 T cells from patients who later developed VAP expressed lower levels of IFNg at the time of 306 intubation. This difference may relate to species-specific variations in immune signaling or intrinsic 307 differences in the host response to influenza virus versus SARS-CoV-2 14,18 . 308

We asked whether certain cell types were responsible for driving the early suppression of 309 immune signaling observed in COVID-19 patients who went on to develop VAP. No significant 310 differences in proportions of the most abundant cell types -monocytes/macrophages, neutrophils 311 or T cells -was observed between patients with or without VAP at the time of intubation. This 312 finding suggests that an impairment of immune cell recruitment was not causing these differences, 313 but rather significant gene expression differences within each of these immune cell populations. we initially hypothesized that differences in viral load between groups might relate to individual 326 VAP susceptibility. However, we found no difference between groups at the "early" timepoint. could not practically be done otherwise and was deemed to be minimal risk by the UCSF IRB, if 406 a patient was unable and a surrogate was not available to provide consent, patients were enrolled 407 with waiver of initial consent, including the collection of biological samples. 408

Specifically, for subjects who were unable to provide informed consent at the time of 409 enrollment, our study team was permitted to collect biological samples as well as clinical data 410 from the medical record obtained prior to consent. Surrogate consent was vigorously pursued for 411 all patients; moreover, each patient was regularly examined to determine if and when s/he was 412 able to consent for him/herself, and the nursing and ICU staff were contacted daily for information 413 about surrogates' availability. For patients whose surrogates provided informed consent, follow-414 up consent was subsequently obtained from the patient if they survived their acute illness and 415 regained the ability to consent. For subjects who died prior to the consent being obtained, a full 416 waiver of consent was approved by the UCSF IRB for both cohort studies. Lack of a surrogate to 417 provide consent is common in critically ill patients. To address this, the UCSF IRB also approved 418 a full waiver of consent for subjects in the COVID-19 cohort who remained unable to provide 419 informed consent and had no contactable surrogate identified within 28 days. Before utilizing this 420 waiver, we made and documented at least three separate attempts to identify and contact the 421 patient or surrogate over a month-long period. While most patients enrolled were consented by 422 typical processes, three died prior to consent being obtained, and five were included with a full 423 waiver of consent due to lack of ability to consent and lack of contactable surrogate. No personally 424 identifiable information has been included as part of this manuscript for any enrolled patients. 425 426

A total of 84 adults who required intubation for severe COVID-19 (Cohort 1) and who had 428 available TA samples were considered for inclusion in the study (Figure 1) Genes were retained for differential expression analysis if they had counts in at least 30% 471 of samples. Differential expression analysis was performed using the R package DESeq2 31 . We 472 modeled the expression of individual genes using the design formula ~VAPgroup, where VAP 473 groups were "VAP-early", "No VAP-early", "VAP-late" and "No VAP-late" and used the results() 474 function to extract a specific contrast. Separate comparisons to the control group were performed 475 using the design formula ~COVID-19-status to compare positive and negative patients. 476

Significant genes were identified using a Benjamini-Hochberg false discovery rate (FDR) 477 < 0.1. We generated heatmaps of the top 50 differentially expressed genes by FDR. For 478 visualization, gene expression was normalized using the regularized log transformation, centered, 479 and scaled prior to clustering. Heatmaps were generated using the pheatmap package. Columns 480 were clustered using Euclidean distance and rows were clustered using Pearson correlation. 481

Differential expression analysis results are provided in (Supplementary data file 1) . 482 483 Pathway analysis 484

Gene set enrichment analyses (GSEA) were performed using the fgseaMultilevel function 485 in the R package fgsea 32 and REACTOME pathways 33 with a minimum size of 10 genes and a 486 maximum size of 1,500 genes. All genes were included in the comparison, pre-ranked by the test 487 statistic. Significant pathways were defined as those with a Benjamini-Hochberg adjusted p-value 488 < 0.05. Ingenuity Pathway Analysis (IPA) Canonical Pathway and Upstream Regulator Analysis 34 489 was employed on genes with p<0.1 and ranked by the test statistic to identify cytokine regulators. 490

Significant IPA results were defined as those with a Z-score absolute value greater than 2 and an 491 overlap P value < 0.05. The gene sets in figures were selected to reduce redundancy and highlight 492 diverse biological functions. Full GSEA and IPA results are provided in (Supplementary data  493   files 2 and 3) . After collection, fresh TA was transported to a BSL-3 laboratory at ambient temperature 508 to improve neutrophil survival. 3mL of TA was dissociated in 40mL of PBS with 50ug/mL 509 collagenase type 4 (Worthington) and 0.56 ku/mL of Dnase I (Worthington) for 10 minutes at room 510 temperature, followed by passage through a 70µM filter. Cells were pelleted at 350g 4C for 10 511 minutes, resuspended in PBS with 2mM EDTA and 0.5% BSA, and manually counted on a 512

hemocytometer. Cells were stained with MojoSort Human CD45 and purified by the 513 manufacturer's protocol (Biolegend). After CD45 positive selection, cells were manually counted 514 with trypan blue on a hemocytometer. Using a V(D)J v1.1 kit according to the manufacturer's 515 protocol, samples were loaded on a 10X Genomics Chip A without multiplexing, aiming to capture 516 10,000 cells (10X Genomics). Libraries underwent paired end 150 base pair sequencing on an 517 Illumina NovaSeq6000. 518

Raw sequencing reads were aligned to GRCh38 using the STAR aligner 35 . Cell barcodes 519 were then determined based upon UMI count distribution. Read count matrices were generated 520 through the 10X genomics cellranger pipeline v3.0. Data was processed and analyzed using the 521 Scanpy v1.6 36 . Cells that had <200 genes and had greater than 30,000 counts were filtered. 522

Mitochondrial genes were removed and multi-sample integration was performed using Harmony 523 v0.1.4 37 . Differential expression was performed using MAST v1.16.0 38 . Due to the significantly 524 greater number of differentially expressed genes in scRNA-seq analyses, we used a more 525 restrictive cutoff of FDR < 0.05 for significant genes. Differential expression analysis results are 526 detailed in (Supplementary data file 4) . was employed on genes with p<0.05 and ranked by log2foldchange to identify canonical pathways 531 and cytokine regulators. We utilized a more restrictive p value cutoff for scRNA-seq to ensure a 532 similar number of genes were input into IPA. Significant IPA results were defined as those with a 533 Z-score absolute value greater than 2 and an overlap P value < 0.05. The gene sets in figures 534 were selected to reduce redundancy and highlight diverse biological functions. Full GSEA and 535 IPA results are provided in (Supplementary data files 5 and 6) . 536 537 Lung microbiome analysis 538 RNA from tracheal aspirates was sequenced as described above. Taxonomic alignments 539 were obtained from raw sequencing reads using the IDseq pipeline 39,40 , which performs quality 540 filtration and removal of human reads followed by reference-based taxonomic alignment at both 541 the nucleotide and amino acid level against sequences in the National Center for Biotechnology 542 Information (NCBI) nucleotide (NT) and non-redundant (NR) databases, followed by assembly of 543 reads matching each taxon detected. Taxonomic alignments underwent background correction 544 for environmental contaminants (see below), viruses were excluded, and data was then 545 aggregated to the genus level before calculating diversity metrics. Alpha diversity (Shannon's 546 Diversity Index) and beta diversity (Bray-Curtis dissimilarity) were calculated and the latter plotted 547 Two patient cohorts were studied. Cohort 1 consisted of COVID-19 patients from the COVID Multiphenotyping for Effective Therapies (COMET) / Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC) studies (described in Methods). Cohort 2 consisted of critically ill intubated control patients from a prior prospective cohort study led by our research group 18 . The "early" samples were the first available tracheal aspirate specimens after intubation. For COVID-19 patients who developed VAP, the "late" samples were obtained a median of two days before VAP onset. Timing of sample collection with respect to VAP versus No-VAP groups was matched at "early" and "late" time points. Controls included eight critically ill, mechanically ventilated patients without LRTI. All COVID-19 patients included in the primary bulk analysis were also included in the longitudinal host expression and microbiome analyses. Abbreviations: VAP=ventilator-associated pneumonia; TA=tracheal aspirate; QC=quality control; sc or scRNA-seq= single cell RNA sequencing; PNA=pneumonia; CDC=United States Centers for Disease Control and Prevention. Excluded from primary analysis: -N=5 meeting CDC-VAP criteria but with negative cultures (2' analysis) -N=24 with bacterial PNA but not meeting CDC VAP criteria (excluded) Figure 2 : COVID-19 VAP is associated with a lower respiratory tract transcriptional signature of bacterial infection 2 days before VAP onset. A) Heatmap of the top 50 differentially expressed genes by adjusted P-value between COVID-19 patients who developed VAP (yellow) versus those who did not (red) at the "late" time-point, 2 days before the onset of VAP, from bulk RNA-seq. B) Gene set enrichment analysis (GSEA) at the "late" time-point based on differential gene expression analyses. GSEA results were considered significant with an adjusted P-value <0.05. C) Ingenuity Pathway Analysis (IPA) of upstream cytokines at the "late" time-point based on differential gene expression analyses. IPA results were considered significant with a Z-score absolute value >2 and overlap P-value <0.05. *Denotes cytokines with an overlap P-value < 0.1. All pathways and cytokines are shown in Supplementary data files 2 and 3.

Heatmap of the top 50 differentially expressed genes by adjusted P-value between COVID-19 patients who developed VAP (blue) versus those who did not (green) at the "early" time-point from bulk RNA-seq. B) Gene set enrichment analysis at the "early" time-point based on differential gene expression analyses. GSEA results were considered significant with an adjusted P-value <0.05. C) Expression of GSEA pathways at the "early" time-point with respect to a baseline of uninfected, intubated controls. Pathways were selected from the GSEA results if they had an adjusted P-value <0.05 in at least one of the comparisons (VAP vs controls or No-VAP vs controls). Pathways with an adjusted P-value <0.05 when compared to controls are indicated by circles with a black outline. D) Ingenuity Pathway Analysis (IPA) of upstream cytokines at the "early" time-point based on differential gene expression analyses. IPA results were considered significant with a Z-score absolute value >2 and overlap P-value <0.05. *Denotes cytokines with an overlap P-value <0.1. All pathways and cytokines are shown in Supplementary data files 2 and 3.

A) UMAP of single cell RNA-seq data from patients that do or do not develop VAP at the "early" time-point, annotated by cell type. B) Cell type proportions in single cell RNA-seq from VAP and No-VAP patients at the "early" time-point. Bars represent the median with IQR. Statistical significance was determined by Mann-Whitney tests. None of the cell types were significantly different with a p-value <0.05. The p-values for each cell type are as follows: B cells: 0.073; Neutrophils: 0.28; T/NK cells: 0.21; Secretory: 0.46; Ciliated: 0.94, and Mono/Mac: 0.81. C) Volcano plot displaying the differentially expressed genes between VAP and No-VAP patients in monocytes and macrophages. D) Ingenuity Pathway Analysis (IPA) of key canonical pathways and upstream cytokines based on differential gene expression analysis in monocytes and macrophages of patients who develop VAP versus those who do not, with adjusted p-values < 0.05. Only significant pathways (IPA Z-score of >2 or <-2 and overlap p-value <0.05) are shown. E) Volcano plot displaying the differentially expressed genes between VAP and No-VAP patients in neutrophils. F) IPA of canonical pathways and upstream cytokines based on differential gene expression analysis in neutrophils of patients who develop VAP versus those who do not, with adjusted p-values < 0.05. Only significant pathways (IPA Z-score of >2 or <-2 and overlap p-value <0.05) are shown. All pathways and cytokines are shown in Supplementary data files 5 and 6.

Heatmap of the top 50 differentially expressed genes by adjusted P-value between COVID-19 patients who developed VAP at the "early" time-point (blue) versus the "late" time-point (yellow) from bulk RNA-seq. B) Gene set enrichment analysis (GSEA) based on differential gene expression of VAP patients at the "early" vs "late" time-point from bulk RNA-seq. GSEA results were considered significant with an adjusted P-value <0.05. C) Ingenuity Pathway Analysis (IPA) of upstream cytokines based on differential gene expression analyses of VAP patients at the "early" vs "late" time-point from bulk RNA-seq. IPA results were considered significant with a Zscore absolute value >2 and overlap P-value <0.05. (D-E) Ingenuity Pathway Analysis (IPA) of key canonical pathways based on differential gene expression analysis in monocytes and macrophages (D) or neutrophils (E) from scRNA-seq of patients who develop VAP versus those who do not, with adjusted p-values < 0.05. Only significant pathways (IPA Z-score of >2 or <-2 and overlap p-value <0.05) are shown. All pathways and cytokines are shown in Supplementary data files 2, 3, 5, and 6. (F-I) Longitudinal analysis of selected pathway expression in VAP (blue) versus No-VAP (green) patients from bulk RNA-seq samples taken from time of intubation to onset of VAP for all patients. Pathway Z-scores were calculated by averaging Z-scores for the top 20 leading edge genes of each pathway, determined by the results of GSEA comparing VAP versus No-VAP patients at the "early" time-point. Multiple Z-scores per patient at a given time interval were averaged so that each patient corresponds to one datapoint at each interval. Samples from day 21+ after intubation are not shown due to a lack of these later time-points in the No-VAP group. VAP onset in these patients ranged from 10-39 days post intubation. Selected pathways are innate immune system (F), neutrophil degranulation (G), cytokine signaling (H), and adaptive immune system (I). Box plots represent the median and range. Statistical significance was determined by two-way ANOVA, and interaction p-values are shown. Individual immune responses to SARS-CoV-2 infection drive a restructuring of the microbial community and increase susceptibility to VAP. Those predisposed to VAP have increased type I interferon responses and dysregulated antibacterial immune signaling characterized by impaired macrophage, neutrophil and T cell activity, decreased TLR signaling and impaired activation of key cytokines important for pathogen defense including IL-1, IL-6, IL-8, TNF, and IL-17. This state of suppressed immunity disrupts the lower respiratory tract microbiome, predisposing to outgrowth of bacterial pathogens and VAP.

Integrating host response and unbiased microbe detection for lower 593 respiratory tract infection diagnosis in critically ill adults

Loss of bacterial diversity during antibiotic treatment of intubated 596 patients colonized with Pseudomonas aeruginosa

Upper airway gene expression reveals suppressed immune responses to 600

SARS-CoV-2 compared with other respiratory viruses

CXCR6 regulates localization of tissue-resident memory CD8 T cells to the 603 airways

Antigen-Induced but Not Innate Memory CD8 T Cells Express NKG2D

Are Recruited to the Lung Parenchyma upon Viral Infection

T cell activation

COVID-19 ARDS is characterized by a dysregulated host response that 610 differs from cytokine storm and is modified by dexamethasone

Imbalanced host response to SARS-CoV-2 drives development of 613 COVID-19

Sustained desensitization to bacterial Toll-like receptor ligands after 615 resolution of respiratory influenza infection

Inhibition of pulmonary antibacterial defense by interferon-gamma 617 during recovery from influenza infection

Early induction of functional SARS-CoV-2-specific T cells associates with 619 rapid viral clearance and mild disease in COVID-19 patients

Lowering the Threshold of Lung Innate Immune Cell Activation Alters 622

Susceptibility to Secondary Bacterial Superinfection

The microbiota of the respiratory 624 tract: gatekeeper to respiratory health

Rhinovirus Infection Induces Degradation of Antimicrobial Peptides and 626

Secondary Bacterial Infection in Chronic Obstructive Pulmonary Disease

Outgrowth of the Bacterial Airway Microbiome after Rhinovirus 629

Exacerbation of Chronic Obstructive Pulmonary Disease

Cell-surface signatures of immune dysfunction risk-stratify critically 632 ill patients: INFECT study

Evaluation of the External RNA Controls Consortium (ERCC) reference 634 material using a modified Latin square design

Near-optimal probabilistic RNA-seq 636 quantification

Differential analyses for RNA-seq: transcript-638 level estimates improve gene-level inferences

Moderated estimation of fold change and dispersion for 640 RNA-seq data with DESeq2

Fast gene set enrichment analysis

The Reactome pathway knowledgebase

STAR: ultrafast universal RNA-seq aligner

SCANPY : large-scale single-cell gene expression 649 data analysis

Fast, sensitive, and accurate integration of single cell data with 651

MAST: a flexible statistical framework for assessing transcriptional changes 653 and characterizing heterogeneity in single-cell RNA sequencing data

Metagenomic next-generation sequencing of samples from pediatric 656 febrile illness in Tororo

IDseq-An open source cloud-based pipeline and analysis service for 658 metagenomic pathogen detection and monitoring

Acknowledgements: This study was performed with support from the National Institute of Allergy 666 and Infectious Diseases-sponsored Immunophenotyping Assessment in a COVID-19 Cohort 667 (IMPACC) Network. We gratefully appreciate support from Amy Kistler

Funding: Funding for the COMET cohort enrollment, sample collection and data analysis derived 671 from

Funding for enrollment of COMET participants not 674 enrolled in IMPACC and for all sample collection and data analysis derived from

01A1 (CL), K24HL137013 (PGW), F32 HL151117 (AS), R35 HL140026 (CSC), and the Chan

Philanthropic support was provided from Mark and Carrie Casey

679 680 Author contributions: 681 Conceptualization

Materials and Correspondence: Correspondence and material requests should be addressed to 694

Host gene expression data are available under NCBI GEO 697 accession number GSE168019 for bulk RNA-seq and GSE168018 for scRNA-seq. Raw microbial 698 sequencing alignments are available from NCBI SRA under BioProject PRJNA704082. Code 699 used for differential expression analysis is